A Phase 1 trial of PT-100 (Point Th...
A Phase 1 trial of PT-100 (Point Therapeutics, Inc., Boston, MA) in make subordinates with chemotherapy-induced neutropenia was designed to application of mind the safety of PT-100 and to measure vital current levels of neutrophils and important biological mediators of hematopoiesis, of that kind as G-CSF and IL-6. make liables ...
|